54030-51-2

Usage

Uses

Used in Pharmaceutical Industry:
2,3-dihydro-6,7-dimethyl-2-thioxo-1H-pteridin-4-one is used as a therapeutic agent for the treatment of gout and hyperuricemia, serving to lower uric acid levels in the blood. Its application is crucial in managing and preventing the painful symptoms and complications of these conditions, such as kidney stones and certain types of kidney disease.
Used in Gout Management:
2,3-dihydro-6,7-dimethyl-2-thioxo-1H-pteridin-4-one is utilized as a uric acid-lowering medication in the management of gout, helping to reduce the frequency and severity of gout attacks and supporting long-term joint health.
Used in Kidney Stone Prevention:
As a xanthine oxidase inhibitor, 2,3-dihydro-6,7-dimethyl-2-thioxo-1H-pteridin-4-one is employed in the prevention of kidney stones, particularly those composed of monosodium urate, by reducing the formation of uric acid and promoting its excretion.
Used in Kidney Disease Treatment:
2,3-dihydro-6,7-dimethyl-2-thioxo-1H-pteridin-4-one is applied in the treatment of specific kidney diseases where the reduction of uric acid levels is beneficial, supporting overall kidney function and health.

InChI:InChI=1/C8H8N4OS/c1-3-4(2)10-6-5(9-3)7(13)12-8(14)11-6/h1-2H3,(H2,10,11,12,13,14)

Upstream product

• 431-03-8 dimethylglyoxal 
• 1004-76-8 4,5-diamino-6-hydroxy-2-thiopyrimidine 
• 1004-76-8 5,6-diamino-2-thioxo-2,3-dihydropyrimidin-4(1H)-one 

Downstream Products

• 63012-79-3 2,3-dimethyl-8,9-dihydro-thiazolo[3,2-a]pteridin-5-one 
• 63012-77-1 7,8-dimethyl-2,3-dihydro-thiazolo[2,3-b]pteridin-5-one 
• 1384266-18-5 [Au(P(C₆H₅)3)((CH₃)2C₄N₂C₂HN₂OS)] 

Relevant academic research and scientific papers

Gold(I) complexes incorporating emissive mercapto-pteridine ligands: Syntheses, X-ray structure, luminescence and preliminary cytotoxic evaluation

The syntheses of six new mixed P/S-donor two-coordinate AuI complexes are described. The complexes incorporate a pteridinyl ligand coordinated through a thiolate donor, and an ancillary tertiary phosphane (PPh3 or PCy3). The mercapto-pteridine ligands (L 1-L3) differ in the nature of the substituents on the pteridine core. An X-ray crystal structure was obtained for one of the examples, [(L1)Au(PPh3)], revealing weak intermolecular interactions between two molecules of the complex: π-π contacts between aromatic rings appear to support an intermolecular Au-Au contact of approximately 3.05 A. All of the complexes are luminescent in solution, with emission arising from tuneable ligand-based excited states, and characterised as a perturbed fluorescence in nature. In this context, complexes of L3 displayed useful visible absorption and emission. Preliminary cytotoxicity assessments were conducted using the MTT assay, and the complexes each displayed impressive anti-proliferative activities (IC50 a given pteridine moiety, triphenylphosphane appeared to be the co-ligand of choice for enhancing biological activity. Copyright

Syntheses of novel heterocycles as anticancer agents

Several pteridine analogues 4-13, 23-26 have been synthesized and tested in vitro against three cancer cell lines, MCF7 (breast), NCI-H460 (lung) and SF-268 (CNS). All tested pteridines can serve as novel templates for the anticancer chemotherapy and can serve as new leads in cancer chemotherapy.